Legal & General Group’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
BI
DTC
CAM
MB
WAM
LGM
Legal & General Group's MLTX Position: Q1 2026 in Review
Legal & General Group increased its MoonLake Immunotherapeutics (MLTX) stake by 28% in Q1 2026, buying an estimated $74.2K and bringing the position to 20,559 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #2433.
Legal & General Group first reported a position in MLTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.05M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.
- Legal & General Group held 20,559 shares of MoonLake Immunotherapeutics worth $383K as of Q1 2026.
- Legal & General Group bought 4,481 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $74.2K.
- MoonLake Immunotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2433 holding.
- Legal & General Group first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 8 quarters since.
- Legal & General Group's MoonLake Immunotherapeutics position peaked at $1.05M in Q4 2024.
- 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.